Actively Recruiting
Assessment of the Initial Efficacy and Safety of BRM424 Ophthalmic Solutions in Patients With Neurotrophic Keratitis
Led by BRIM Biotechnology Inc. · Updated on 2024-10-28
12
Participants Needed
1
Research Sites
69 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The objective of this study is to obtain initial efficacy of BRM424 in patients with Stage 2 and Stage 3 NK and evaluate safety and tolerability.
CONDITIONS
Official Title
Assessment of the Initial Efficacy and Safety of BRM424 Ophthalmic Solutions in Patients With Neurotrophic Keratitis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Be at least 18 years of age
- Provide written informed consent
- Have Neurotrophic Keratitis Stage 2 (persistent epithelial defect) or Stage 3 (corneal ulcer)
You will not qualify if you...
- Have any active ocular infection (bacterial, viral, fungal or protozoal) or active ocular inflammation not related to Neurotrophic Keratitis
- Anticipate needing to use therapeutic contact lenses or wear contact lenses for vision correction during the 28-day treatment period in the eye with Neurotrophic Keratitis
- Are a woman of childbearing potential not using an acceptable method of birth control
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Wilmington Eye
Leland, North Carolina, United States, 28451
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here